Triple Antibiotic Combinations for Drug-Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing global issue of antimicrobial resistance in bacteria is outpacing the development and effectiveness of existing antibiotics, necessitating a more sustainable and cost-effective solution to combat drug-resistant infections.
Innovation Solution
Development of synergistic combinations of three or more known antibiotics, which demonstrate greater biological activity than the additive effect, effectively targeting both gram-negative and gram-positive bacteria at lower doses, thereby reducing the risk of developing further resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new chemical entities (NCEs) are developed to combat antimicrobial resistance, then effectiveness against resistant bacteria is improved, but development time and cost increase significantly
Solution Approach 1:
The patent combines three or more existing antibiotics into synergistic combinations to achieve enhanced effectiveness against antimicrobial-resistant bacteria. This merging approach allows the use of known, approved drugs in combination to produce a therapeutic effect greater than the sum of individual agents, thereby avoiding the lengthy NCE development process while maintaining reliability.
Solution Approach 2:
The patent changes the dosing parameters and combination ratios of existing antibiotics to optimize their synergistic effect. By adjusting concentrations and administration protocols, the combination achieves improved effectiveness against resistant strains without requiring new chemical entities, thus reducing development time while maintaining therapeutic reliability.
2Reliability
If new chemical entities (NCEs) are developed to combat antimicrobial resistance, then effectiveness against resistant bacteria is improved, but development cost increases significantly
Solution Approach 1:
The patent merges three or more existing antibiotics into synergistic combinations, leveraging the safety and efficacy data already established for each individual agent. This approach eliminates the need for expensive de novo development, clinical trials, and regulatory approval processes for new molecules, thereby achieving cost-effective treatment of resistant infections.
Solution Approach 2:
The patent replicates the successful clinical profiles of individual approved antibiotics within a combination regimen, utilizing their known safety and efficacy characteristics. This copying of proven therapeutic agents into a synergistic framework avoids the substantial costs associated with creating and validating entirely new chemical entities.
3Reliability
If higher doses of single antibiotics are used to overcome resistance, then bacterial killing effect is improved, but toxicity increases
Solution Approach 1:
The patent combines three or more antibiotics at lower individual doses to achieve synergistic bacterial killing. This merging strategy allows each agent to contribute to the overall effect at sub-toxic levels, producing a cumulative bactericidal effect that exceeds what could be achieved with higher doses of any single antibiotic, thereby improving reliability while reducing toxicity.
4Reliability
If combinations of three or more antibiotics are used to achieve synergy, then effectiveness against resistant bacteria is improved, but treatment complexity increases
Solution Approach 1:
The patent combines three or more antibiotics into fixed synergistic formulations, merging multiple agents into a coordinated treatment regimen. This approach manages complexity by establishing predefined combination protocols and dosing schedules, making the multi-agent therapy as manageable as single-agent treatments while achieving superior effectiveness against resistant bacteria.
Data Source
AI summary
The present invention provides an antimicrobial combination comprising three different antimicrobial agents The first antimicrobial agent is selected from ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives thereof; the second antimicrobial agent is selected from zidovudine, doxycycline, fosfomycin and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from levofloxacin, doxycycline, fosfomycin, meropenem, rifampicin, gentamicin, polymyxin B/E, and pharmaceutically acceptable derivatives thereof; wherein the combination includes at least one of levofloxacin, doxycycline, rifampicin, fosfomycin, or a pharmaceutically acceptable derivative thereof; provided the combination is not (1) polymyxin E/B, zidovudine and rifampicin or (2) ceftazidime, zidovudine and fosfomycin. Also provided is an antimicrobial combination comprising three antimicrobial agents, wherein the first antimicrobial agent is ceftazidime or a pharmaceutically acceptable derivative thereof; the second antimicrobial agent is zidovudine or a pharmaceutically acceptable derivative thereof; and the third antimicrobial agent is polymyxin E or a pharmaceutically acceptable derivative thereof.